Polish medtech company Medicalgorithmics has signed another agreement with a leading U.S.-based diagnostics firm – ACS Diagnostics Inc. Under the agreement, the company’s innovative DeepRhythm Platform (DRP) and DeepRhythmAI (DRAI) artificial intelligence algorithms will be integrated with the partner’s flagship device – the multifunctional CORE 3 ECG patch, which holds FDA certification. This marks the tenth agreement signed by Medicalgorithmics in 2025, and the third one with a U.S. partner, confirming the rapidly growing interest in the company’s software and AI algorithms following the breakthrough publication of research results using its AI technology in Nature Medicine.
The launch of services as part of the cooperation with ACS Diagnostics requires integration of the DRP platform with CORE 3 devices – a process for which the company is well prepared. Upon completion of integration, ACS will be able to offer the full spectrum of remote cardiac monitoring services in the U.S. market – from traditional Holter monitoring, through event monitoring, to mobile cardiac telemetry (MCT), which provides the highest reimbursement levels in the U.S. The agreement will also allow Medicalgorithmics to distribute ACS’s high-quality devices to other clients in the U.S., strengthening the company’s offering and accelerating business growth in the region.
– Medicalgorithmics is consistently – and currently even faster than we initially anticipated – gaining new clients in global markets, diversifying its business. The United States, however, remains our largest and most strategic market, which is why each new contract signed in the U.S. brings us satisfaction and confirms the effectiveness of our growth strategy. The cooperation with ACS Diagnostics and integration of our software with the CORE 3 device will enable us to offer U.S. partners the full range of advanced services – from traditional Holter monitoring to modern MCT telemetry monitoring using an FDA-certified ECG patch. This is yet another confirmation of our strong position in the demanding U.S. market, as this is already our third agreement in the U.S. and tenth overall this year – says Jarosław Jerzakowski, Board Member at Medicalgorithmics responsible for operations and sales.
ACS Diagnostics Inc. is a fast-growing diagnostic company (IDTF in the U.S.), offering comprehensive ambulatory cardiac monitoring services. Its flagship product – CORE 3 – is a compact, multifunctional ECG recorder (patch) that enables testing in Holter, event monitoring, and MCT modes – all in a single device. ACS also provides remote ECG diagnostic services.